Trial
NCT04197219
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Case Comprehensive Cancer Center
Collaborators
—
Condition
Recurrent Endometrial Cancer
Intervention
Pembrolizumab
Why stopped
PI is leaving institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-05